home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

16th Annual Drug Discovery Summit 2015

 
  February 04, 2015  
     
 
Oxford Global, Berlin, Germany
08th and 09th June 2015


Oxford Global’s 16th Annual Drug Discovery Leaders Summit and our co-located 3rd Annual Discovery Chemistry and Drug Design Congress is Europe’s leading Summit in the drug discovery and discovery chemistry field. Our prestigious Summit brings together prominent decision makers working at the forefront of research into target based discovery, phenotypic screening, preclinical biomarkers, and medicinal chemistry.

Our Summit will consist of 6 interactive streams covering:
  • Target Based Discovery
  • Screening and Assays: Enabling Technologies
  • Preclinical Biomarkers and Translational Medicine
  • Supporting Innovation: Data and Information Management
  • Discovery Chemistry: Latest Case Studies
  • Drug Design: Novel Approaches

On day one our panel of discovery experts will explore the resurgence of phenotypic screening, the latest innovations in high content analysis and the search for physiologically relevant screen models, including 3D cell culture and stem cells. Day one also features a stream dedicated to the latest research in medicinal chemistry.

On day two delegates will hear from our industry leaders about the most promising new technologies for biomarkers and translational medicine, our data and information management stream will host exciting discussions about how to exploit Big Data for more efficient drug discovery and our third stream is dedicated to the most innovative approaches to drug design.
 
 
Organized by: Oxford Global
Invited Speakers:

- Jörg Eder, Executive Director, Novartis Institute for Biomedical Research,
- Chas Bountra, Professor of Translational Medicine in the Nuffield Department of Clinical Medicine, and Chief Scientist, Structural Genomics Consortium
- Jinghai (Jim) Xu, Executive Director, Merck
- Jutta Heim, CEO, Evolva
- Ingo Mügge, Senior Research Fellow, Boehringer Ingelheim
- Stevan Djuric, Senior Director Medicinal Chemistry Technologies, Abbott

- Sara Colombetti, Group leader In Vivo Models, Roche
- Steven England, Director, Head of Future Therapeutics & Technologies, AbbVie
- Nicolas Fischer, Head of Research, Novimmune SA
- Matthias Frech, Head of Molecular Interactions & Biophysics, Merck
- Jutta Helm, CEO, Evolva
- Rod Hubbard, Senior Fellow, Vernalis and Professor, University of York
- Juan-Miguel Jimenez, Senior Director, Head of Chemistry UK, Vertex
- Malin Lemurell,Director Medicinal Chemistry, AstraZeneca 
- Christoph Wiessner,Chief Operating Officer / VP R&D, Asceneuron SA
- Hank Wu,Head of Research IT, Biogen Idec

 
Deadline for Abstracts: N/A
 
Registration:

For further information to know how to register please contact:

g.alonso@oxfordglobal.co.uk

+44 (0)1865 248455

E-mail: g.alonso@oxfordglobal.co.uk
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.